Form 4: Recursion Pharma Director Acquires Shares

Zavain Dar, a Director at Recursion Pharmaceuticals, acquired 2,941 shares of Class A Common Stock as part of the company's director compensation policy.

Summary

• Zavain Dar, a Director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 2,941 shares of Class A Common Stock.
• The transaction occurred on October 1, 2025.
• These shares were issued at a price of $0, indicating they were an award rather than a purchase.
• The acquisition was made pursuant to the Issuer's Outside Director Compensation Policy.
• Following this transaction, Dar Zavain directly beneficially owns 138,758 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The filing indicates a routine insider acquisition of shares by a director as part of a compensation policy, which is generally viewed as a neutral to slightly positive signal of alignment with shareholder interests, without providing significant new financial or operational information.

Positives

• Director Zavain Dar increased his direct beneficial ownership in Recursion Pharmaceuticals by 2,941 shares, aligning his interests further with shareholders.
• The acquisition is part of a structured Outside Director Compensation Policy, indicating a standard and transparent compensation practice.

Negatives

• No negative information is presented in this Form 4 filing.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

This Form 4 filing details a past insider transaction and does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Director compensation, often including equity awards, is a standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to align management and director interests with long-term shareholder value. This transaction reflects a routine implementation of such a policy.

Comparison to Industry Standards

• The issuance of equity as part of outside director compensation is a common practice across industries, including the biotechnology sector, to incentivize long-term commitment and align director interests with shareholder returns.
• Many companies, such as Moderna (MRNA) or BioNTech (BNTX), utilize similar equity-based compensation structures for their non-executive directors.
• The specific number of shares awarded (2,941) would typically be benchmarked against peer companies' director compensation packages, considering the company's market capitalization and the director's responsibilities.

Corporate Governance

Related Party Transactions

• The acquisition of 2,941 shares by Director Zavain Dar as part of the Outside Director Compensation Policy constitutes a related party transaction, which is a standard practice for compensating board members.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with the company's performance and shareholder value.
• Employees: No direct impact mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Zavain Dar, Director, Insider Transaction, Stock Acquisition, Form 4, SEC Filing, Class A Common Stock, Director Compensation